×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: GBA Gene Mutations and Parkinson's Disease Risk
mechanism
3,113 words
KG: ent-gene-694200ea
kind:mechanism
section:mechanisms
state:published
topic:parkinsons
gba
glucocerebrosidase
lysosomal-dysfunction
genetic-risk
Contents
GBA Gene Mutations and Parkinson's Disease Risk
🔬
Protein Info
Gene Symbol
ent-gene-694200ea
Chromosome
1q21
Molecular weight
55.8 kDa (precursor), 50.8 kDa (mature)
Cellular localization
Lysosome
KG Connections
2
knowledge graph edges
Databases
GeneCards
UniProt
NCBI Gene
HPA
STRING
Knowledge Graph
Related Hypotheses (30)
Multi-Modal CRISPR Platform for Simultaneous Editing and Mon
Score: 0.42
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Microbial Inflammasome Priming Prevention
Score: 0.58
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Chromatin Accessibility Restoration via BRD4 Modulation
Score: 0.56
Vagal Afferent Microbial Signal Modulation
Score: 0.52
Epigenetic Memory Erasure via TET2 Activation
Score: 0.52
Context-Dependent CRISPR Activation in Specific Neuronal Sub
Score: 0.51
Vocal Cord Neuroplasticity Stimulation
Score: 0.50
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.47
Epigenetic Memory Reprogramming for Alzheimer's Disease
Score: 0.47
Arginine Methylation Enhancement Therapy
Score: 0.46
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci
Score: 0.45
Programmable Neuronal Circuit Repair via Epigenetic CRISPR
Score: 0.42
Synthetic Biology Rewiring via Orthogonal Receptors
Score: 0.42
Temporal TET2-Mediated Hydroxymethylation Cycling
Score: 0.41
Partial Neuronal Reprogramming via Modified Yamanaka Cocktai
Score: 0.40
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.40
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.40
The Glial Ketone Metabolic Shunt Hypothesis
Score: 0.40
KDM6A-Mediated H3K27me3 Rejuvenation
Score: 0.38
Nucleolar Stress Response Normalization
Score: 0.38
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.38
Microglia-Derived Extracellular Vesicle Engineering for Targ
Score: 0.37
DNMT1-Targeting Antisense Oligonucleotide Reset
Score: 0.36
Show 25 more
Related Analyses (30)
Does TFEB activation directly restore mutant GBA enzyme acti
molecular biology · failed
What is the therapeutic window between GCS inhibition effica
neurodegeneration · failed
GBA-Synuclein Loop: Therapeutic Strategies for Parkinson's D
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Show 25 more
Related Experiments (30)
Validate Mitochondria-Lysosome Contact Site Dysfunction in P
validation · proposed · Score: 0.46
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.46
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.46
Genetic Risk Modifiers in DLB Phenotype
clinical · proposed · Score: 0.46
DLB Treatment Response Biomarkers — Predicting Cholinesteras
clinical · proposed · Score: 0.46
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.46
GLP-1 Agonist Responder Prediction Study — Precision Medicin
clinical · proposed · Score: 0.46
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · proposed · Score: 0.46
MLCS Quantification in Parkinson's Disease
validation · proposed · Score: 0.46
Experiment: Multi-Ethnic PD GWAS
clinical · proposed · Score: 0.46
Prodromal Parkinson's Disease Biomarker Development — Early
clinical · proposed · Score: 0.46
Synaptic Vesicle Trafficking Dysfunction Validation in Parki
clinical · proposed · Score: 0.46
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.46
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.46
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.46
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.46
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.46
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.46
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.46
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.46
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.46
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.46
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.46
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.46
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.46
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.46
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.46
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.46
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.46
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.46
Show 25 more
See Also (15)
Integrated Stress Response in Neurodegeneration
mechanism · Pages share 5 hypotheses
ALS Therapeutic Landscape — Programs by Phase and Modal
disease · Pages share 4 hypotheses
Wnt/β-Catenin Signaling Pathway in Neurodegeneration
mechanism · Pages share 4 hypotheses
WNK1-Bilirubin Signaling in Neuroinflammation and Neuro
mechanism · Pages share 4 hypotheses
vip-vasoactive-intestinal-peptide-signaling-neurodegene
mechanism · Pages share 4 hypotheses
VEGF Signaling and Cerebral Angiogenesis in Neurodegene
mechanism · Pages share 4 hypotheses
Vagus Nerve Pathway in Neurodegeneration
mechanism · Pages share 4 hypotheses
Ubiquitin-Proteasome System Dysfunction in Neurodegener
mechanism · Pages share 4 hypotheses
ubiquitin-proteasome-dysfunction-neurodegeneration
mechanism · Pages share 4 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 4 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 4 hypotheses
Therapeutic Targets in Neurodegeneration
mechanism · Pages share 4 hypotheses
Tertiary Lymphoid Organs in Neurodegeneration
mechanism · Pages share 4 hypotheses
T-Cell Dysfunction in Neurodegeneration
mechanism · Pages share 4 hypotheses
Synthetic Lethality and PARP Inhibition in Neurodegener
mechanism · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (2 edges)
ent-gene-694200ea
data_in
benchmark_ot_ad_answer_key:GBA
benchmark_ot_ad_answer_key:GBA
data_in
ent-gene-694200ea